Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Alpine Immune Sciences — Collaboration revenue by Year
Alpine Immune Sciences — Collaboration revenue ($M) ($M)
Vertex Pharmaceuticals Alpine Immune Sciences — Collaboration revenue: $58.9M in FY2023, up 95.9% from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
Source: SEC Filing ↗
Reported in SEC XBRL (CIK 0001626199 Alpine Immune Sciences).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Alpine Immune Sciences — Collaboration revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 58.9 | +95.9% | SEC Filing ↗ |
| FY2022 | Dec 31, 2022 | 30.1 | +28.2% | SEC Filing ↗ |
| FY2021 | Dec 31, 2021 | 23.4 | +151.2% | SEC Filing ↗ |
| FY2020 | Dec 31, 2020 | 9.33 | +436.2% | SEC Filing ↗ |
| FY2019 | Dec 31, 2019 | 1.74 | +148.6% | SEC Filing ↗ |
| FY2018 | Dec 31, 2018 | 0.70 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Alpine Immune Sciences — Collaboration revenue ($M), annual FY2018–FY2023 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/alpine-rev
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.